ClinicalTrials.gg

Program

Dolutegravir

Also written as “GSK1349572”, “DTG” and “Dolutegravir 50 mg”.

Its studies are mostly in Infections · HIV Infections · Malaria · Acquired Immunodeficiency Syndrome · Tuberculosis, led by 3 companies.

Furthest: phase 4, since Oct 13, 201766 company-led studies, 3 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline643 open or runningphase 4since Oct 13, 2017Nov 5, 2007Sep 14, 2032phase 3 · NCT07393659
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jun 4, 2024Jun 4, 2024none ahead
Viatris10 open or runningearly phase 1since Jul 28, 2021Jul 28, 2021none ahead

Also a collaborator on its studies: ppd-development-lp, Johnson & Johnson and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jan 22, 2009.

  1. Oct 13, 2017Phase 4 study in InfectionsGlaxoSmithKline · NCT03314064 · 43 enrolled · Russian Federation
  2. Jan 5, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03446573 · 743 enrolled · United States, Australia, Belgium and more
  3. Sep 21, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
  4. Jan 22, 2019Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT03816696 · 16 enrolled · United States
  5. Apr 17, 2019Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT03921723 · 22 enrolled · United Kingdom
  6. May 8, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03945981 · 131 enrolled · United States
  7. Jul 11, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
  8. Apr 28, 2021Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT04871113 · 62 enrolled · United States, Argentina, Brazil and more
  9. Jul 28, 2021Viatris's first study: early phase 1 study in HIV-1-infectionNew to ViatrisViatris · NCT05030025 · 43 enrolled · Canada
  10. Dec 7, 2022Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT05674656 · 20 planned · United States
  11. Jun 9, 20232 phase 3 studies in HIV InfectionsGlaxoSmithKline · NCT05911360, NCT05917509
  12. Jul 19, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
  13. Jun 4, 2024Humanis Saglık Anonim Sirketi's first study: phase 1 study in HIV InfectionsNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06450275 · 32 enrolled · Jordan
  14. Jan 30, 2026Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659 · 197 planned · Romania, South Africa, Uganda

Ahead

  1. Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07393659HIV Infections · Romania, South Africa, Uganda3RecruitingGlaxoSmithKlineSep 14, 2032197
NCT06450275HIV Infections · Jordan1CompletedHumanis Saglık Anonim SirketiJan 15, 202432
NCT05979311HIV Infections · Argentina, Belgium, Denmark and more3Active, not recruitingGlaxoSmithKlineApr 15, 2026463
NCT05917509HIV Infections · United States, Argentina, Canada and more3CompletedGlaxoSmithKlineSep 16, 2025171
NCT05911360HIV Infections · United States, Austria, Belgium and more3CompletedGlaxoSmithKlineJan 23, 2026205
NCT05674656HIV Infections · United States2RecruitingGlaxoSmithKlineJun 1, 202620
NCT05030025HIV-1-infection · CanadaEarly 1CompletedViatrisAug 29, 202143
NCT04871113HIV Infections · United States, Argentina, Brazil and more2CompletedGlaxoSmithKlineOct 27, 202262
NCT04021290HIV Infections · United States, Argentina, Belgium and more3CompletedGlaxoSmithKlineApr 23, 2021493
NCT03945981HIV Infections · United States3CompletedGlaxoSmithKlineApr 29, 2020131
NCT03921723HIV Infections · United Kingdom1CompletedGlaxoSmithKlineJul 25, 201922
NCT03816696HIV Infections · United States1CompletedGlaxoSmithKlineMar 30, 201916
NCT03682848HIV Infections · Kenya, South Africa, Thailand3CompletedGlaxoSmithKlineDec 1, 202132
NCT03446573HIV Infections · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineMay 20, 2019743
NCT03314064Infections · Russian Federation4CompletedGlaxoSmithKlineOct 1, 201843
NCT03078556Infections · United States1CompletedGlaxoSmithKlineAug 18, 2017154
NCT03016533HIV Infections · United States, Botswana, Brazil and more3CompletedGlaxoSmithKlineDec 24, 2024100
NCT02893488Infections · United States1CompletedGlaxoSmithKlineNov 1, 201620
NCT02741557Infections · United States1CompletedGlaxoSmithKlineOct 24, 2016118
NCT02738931Infections · United States1CompletedGlaxoSmithKlineJun 201630
NCT02715479Infections · United States1CompletedGlaxoSmithKlineMay 201614
NCT02227238HIV Infections · Argentina, Brazil, Chile and more3CompletedGlaxoSmithKlineAug 2, 2017627
NCT02185300Infections · United States1CompletedGlaxoSmithKlineSep 201415
NCT02178592Infections · Argentina, Brazil, Mexico and more3CompletedGlaxoSmithKlineNov 2, 2017113
NCT02105987Infections · United States, Canada, Puerto Rico3CompletedGlaxoSmithKlineApr 2015555
NCT02082808Infections · United States1CompletedGlaxoSmithKlineMay 201412
NCT02075593Infections · Russian Federation, Spain3CompletedGlaxoSmithKlineOct 22, 20184
NCT02064374Infections · United States1CompletedGlaxoSmithKlineMay 201430
NCT01967771Infections · United States1CompletedGlaxoSmithKlineJan 201416
NCT01910402Infections · United States, Argentina, Canada and more3CompletedGlaxoSmithKlineSep 22, 2015499
NCT01622790Infections · United States1CompletedGlaxoSmithKlineAug 201266
NCT01568892HIV Infections · United States3CompletedGlaxoSmithKlineOct 31, 201230
NCT01536873Infections · United States, Austria, Belgium and more–CompletedGlaxoSmithKlineSep 23, 2016200
NCT01498861Infections · United States1CompletedGlaxoSmithKlineMar 201216
NCT01499199Infections · United States3CompletedGlaxoSmithKlineOct 201213
NCT01467531Infections · United States1CompletedGlaxoSmithKlineFeb 201228
NCT01467518Infections · Canada1CompletedGlaxoSmithKlineFeb 201211
NCT01449929Infections · United States, France, Germany and more3CompletedGlaxoSmithKlineApr 22, 2013488
NCT01425099Infections · United States1CompletedGlaxoSmithKlineOct 201112
NCT01382238Infections · United States1CompletedGlaxoSmithKlineAug 201120
NCT01366547Infections · United States1CompletedGlaxoSmithKlineJul 201118
NCT01353716Infections · United States1CompletedGlaxoSmithKlineApr 201216
NCT01332565Infections · United States1CompletedGlaxoSmithKlineJun 201110
NCT01328041Infections · United States, Belgium, Canada and more3CompletedGlaxoSmithKlineMay 2012183
NCT01283100Infections · United States1WithdrawnGlaxoSmithKlineMar 20110
NCT01231516Infections · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineFeb 4, 2013724
NCT01231529Infections · United States1CompletedGlaxoSmithKlineJun 4, 201116
NCT01227824Infections · United States, Australia, Canada and more3CompletedGlaxoSmithKlineFeb 6, 2012828
NCT01214993Infections · United States1CompletedGlaxoSmithKlineNov 201038
NCT01209065Infections · United States1CompletedGlaxoSmithKlineNov 201027
NCT01098513Infections · United States1CompletedGlaxoSmithKlineJun 201024
NCT01098526Infections · United States1CompletedGlaxoSmithKlineMay 26, 201012
NCT01068925Infections · United States1CompletedGlaxoSmithKlineApr 5, 201018
NCT00996021Healthy Subjects · United States1CompletedGlaxoSmithKlineNov 200942
NCT00951015Infections · United States, France, Germany and more2CompletedGlaxoSmithKlineFeb 26, 2010208
NCT00950859Infections · United States, Canada, France and more2CompletedGlaxoSmithKlineNov 201051
NCT00942136HIV Infections · United States1CompletedGlaxoSmithKlineSep 200924
NCT00883935Healthy Volunteer · United States1CompletedGlaxoSmithKlineJun 200924
NCT00867152Healthy Volunteer · United States1CompletedGlaxoSmithKlineMay 200917
NCT00858455Healthy Volunteer · United States1CompletedGlaxoSmithKlineMar 200916

How it is read

Names in the registry

  • “GSK1349572”, 20 entries
  • “Dolutegravir”, 12 entries
  • “DTG”, 6 entries
  • “Dolutegravir 50 mg”, 4 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.